Recommendations for screening, monitoring, and referral of pediatric chronic hepatitis B

Pediatrics

Volumn 124, Issue 5, 2009, Pages

  Haber, Barbara A ^a   Block, Joan M ^b   Jonas, Maureen M ^c   Karpen, Saul J ^d   London, W Thomas ^e   McMahon, Brian J ^f   Murray, Karen F ^g   Narkewicz, Michael R ^h   Rosenthal, Philip ⁱ   Schwarz, Kathleen B ^j  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b HEPATITIS B FOUNDATION   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e FOX CHASE CANCER CENTER   (United States)

^f ALASKA NATIVE MEDICAL CENTER   (United States)

^g UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Chronic; Disease management; Hepatitis B; Liver; Pediatrics; Screening

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ALPHA2B INTERFERON; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; TELBIVUDINE; TENOFOVIR DISOPROXIL; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS; ECHOGRAPHY; ETHNIC DIFFERENCE; GENERAL PRACTITIONER; GENOTYPE; HEALTH CARE ORGANIZATION; HEPATITIS B; HUMAN; IMMUNOPROPHYLAXIS; MEDICAL SPECIALIST; PATHOPHYSIOLOGY; PATIENT MONITORING; PATIENT REFERRAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCREENING; SEROCONVERSION; VACCINATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DNA, VIRAL; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INFANT; REFERRAL AND CONSULTATION; VACCINATION;

EID: 70350519979     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2009-0567     Document Type: Article

References (33)

1. Fwu CW, Chien YC, Kirk GD, et al. Hepatitis B virus infection and hepatocellular carcinoma amongparous Taiwanese women: nationwide cohort study. J Natl Cancer Inst. 2009;101(14):1019-1027
2. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine Preventable Diseases. 10th ed, 2nd printing. Washington, DC: Public Health Foundation; 2008:211-234. Available at: www.cdc.gov/vaccines/pubs/ pinkbook/pink-chapters.htm. Accessed January 30, 2009
3. Cohen C, Evans AA, London WT, Block J, Conti M, Block T. Underestimation of chronic hepatitis B virus infection in the United States of America. J Viral Hepat. 2008;15(1):12-13 (Pubitemid 350243575)
4. Beasley RP, Lin CC, Hwang LY, Chien CS. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22 707 men in Taiwan. Lancet. 1981;2(8256):1129-1133
5. Evans AA, Chen G, Ross EA, Shen FM, Lin WY, London WT. Eight-year follow-up of the 90,000-person Haimen City Cohort: I. Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol Biomarkers Prev. 2002;11(4):369-376 (Pubitemid 34408216)
6. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48(2):335-352
7. Fattovich G, Olivari N, Pasino M, D'Onofrio M, Martone E, Donato F. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut. 2008;57(1):84-90
8. Hwang JP, Huang CH, Yi JK. Knowledge about hepatitis B and predictors of hepatitis B vaccination among Vietnamese American college students. J Am Coll Health. 2008;56(4):377-382
9. Centers for Disease Control and Prevention. Screening for chronic hepatitis B among Asian/Pacific Islander populations: New York City, 2005.MMWRMorb Mortal Wkly Rep. 2006;55(18):505-509
10. Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1 - immunization of infants, children, and adolescents [published corrections appear in MMWR Morb Mortal Wkly Rep. 2006;55(6):158-159; and MMWR Morb Mortal Wkly Rep. 2007;56(48):1267]. MMWR Recomm Rep. 2005;54(RR-16):1-31
11. Weinbaum CM, Williams I, Mast EE, et al; Centers for Disease Control and Prevention. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 2008;57(RR-8):1-20. Available at: www.cdc.gov/mmwr/preview/mmwrhtml/rr5708a1. htm. Accessed February 23, 2009
12. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med. 1997;336(26):1855-1859 (Pubitemid 27263972)
13. Chang MH, Chen TH, Hsu HM, et al. Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems. Clin Cancer Res. 2005;11(21):7953-7957
14. Zuckerman JN. Review: hepatitis B immune globulin for prevention of hepatitis B infection. J Med Virol. 2007;79(7):919-921 (Pubitemid 46871547)
15. Shepard CW, Finelli L, Fiore AE, Bell BP. Epidemiology of hepatitis B and hepatitis B virus infection in United States children. Pediatr Infect Dis J. 2005;24(9):755-760 (Pubitemid 41324881)
16. Dayan GH, Caquías CR, García Y, et al. Medical practices for prevention of perinatal infections in Puerto Rico. Paediatr Perinat Epidemiol. 2008;22(1):31-39 (Pubitemid 350308495)
17. Livingston SE, Simonetti JP, Bulkow LR, et al. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology. 2007;133(5):1452-1457 (Pubitemid 350029740)
18. Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35(6):1522-1527 (Pubitemid 34966908)
19. Fung J, Lai CL, But D, Wong D, Cheung TK, Yuen MF. Prevalence of fibrosis and cirrhosis in chronic hepatitis B: implications for treatment and management. Am J Gastroenterol. 2008;103(6):1421-1426 (Pubitemid 351813897)
20. Chen CJ, Iloeje UH, Yang HI. Long-term outcomes in hepatitis B: the REVEAL-HBV study. Clin Liver Dis. 2007;11(4):797-816
21. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295(1):65-73 (Pubitemid 43042691)
22. Lai CL, Yuen MF. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Intern Med. 2007;147(1):58-61
23. Wang CC, Lim LY, Deubner H, et al. Factors predictive of significant hepatic fibrosis in adults with chronic hepatitis B and normal serum ALT. J Clin Gastroenterol. 2008;42(7):820-826
24. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137(1):1-10 (Pubitemid 34705370)
25. McMahon BJ, Bulkow L, Harpster A, et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology. 2000;32(4 pt 1):842-846 (Pubitemid 30744285)
26. Heyward WL, Lanier AP, McMahon BJ, Fitzgerald MA, Kilkenny S, Paprocki TR. Early detection of primary hepatocellular carcinoma: screening for primary hepatocellular carcinoma among persons infected with hepatitis B virus. JAMA. 1985;254(21):3052-3054
27. Livingston SE, Simonetti JP, McMahon BJ, et al. Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma: preponderance of genotype F. J Infect Dis. 2007;195(1):5-11
28. Sokal EM, Kelly DA, Mizerski J, et al. Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B. Hepatology. 2006;43(2):225-232 (Pubitemid 43303990)
29. Pallier C, Rodriguez C, Brillet R, Nordmann P, Hézode C, Pawlotsky JM. Complex dynamics of hepatitis B virus resistance to adefovir. Hepatology. 2009;49(1):50-59
30. Burczynska B, Madalinski K, Pawlowska J, et al. The value of quantitative measurement of HBeAg and HBsAg before interferon-alpha treatment of chronic hepatitis B in children. J Hepatol. 1994;21(6):1097-1102
31. Kobak GE, MacKenzie T, Sokol RJ, Narkewicz MR. Interferon treatment for chronic hepatitis B: enhanced response in children 5 years old or younger. J Pediatr. 2004;145(3):340-345 (Pubitemid 39165682)
32. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol. 2008;6:1315-1341; quiz 1286
33. Lok AS, McMahon BJ. Chronic hepatitis B [published correction appears in Hepatology. 2007;45(6):1347]. Hepatology. 2007;45(2):507-539